New β-lactamase inhibitors: A therapeutic renaissance in an MDR world

Sarah M. Drawz, Krisztina M. Papp-Wallace, Robert A. Bonomo

Research output: Contribution to journalReview articlepeer-review

245 Scopus citations


As the incidence of Gram-negative bacterial infections for which few effective treatments remain increases, so does the contribution of drug-hydrolyzing β-lactamase enzymes to this serious clinical problem. This review highlights recent advances in β-lactamase inhibitors and focuses on agents with novel mechanisms of action against a wide range of enzymes. To this end, we review the β-lactamase inhibitors currently in clinical trials, select agents still in preclinical development, and older therapeutic approaches that are being revisited. Particular emphasis is placed on the activity of compounds at the forefront of the developmental pipeline, including the diazabicyclooctane inhibitors (avibactam and MK-7655) and the boronate RPX7009. With its novel reversible mechanism, avibactam stands to be the first new β-lactamase inhibitor brought into clinical use in the past 2 decades. Our discussion includes the importance of selecting the appropriate partner β-lactam and dosing regimens for these promising agents. This "renaissance" of β-lactamase inhibitors offers new hope in a world plagued by multidrug-resistant (MDR) Gram-negative bacteria.

Original languageEnglish (US)
Pages (from-to)1835-1846
Number of pages12
JournalAntimicrobial agents and chemotherapy
Issue number4
StatePublished - Apr 2014


Dive into the research topics of 'New β-lactamase inhibitors: A therapeutic renaissance in an MDR world'. Together they form a unique fingerprint.

Cite this